PMV Pharmaceuticals
PMVP
106 hedge funds and large institutions have $324M invested in PMV Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 40 increasing their positions, 29 reducing their positions, and 23 closing their positions.
476% more call options, than puts
Call options by funds: $121K | Put options by funds: $21K
38% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 29
32% more capital invested
Capital invested by funds: $246M → $324M (+$78.3M)
0.57% more ownership
Funds ownership: 112.49% → 113.06% (+0.57%)
5% less funds holding
Funds holding: 111 → 106 (-5)
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$3.66M |
| 2 |
BlackRock
New York
|
+$3.39M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$2.92M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
+$2.46M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$3.86M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$3.3M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.59M |
| 4 |
Morgan Stanley
New York
|
-$1.44M |
| 5 |
HF
HRT Financial
New York
|
-$1.28M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
S
126
SignatureFD
Atlanta,
Georgia
| – | -$2.1K | -440 | Closed |
|
127
US Bancorp
Minneapolis,
Minnesota
| – | -$1.76K | -370 | Closed |
|
|
RTL
128
Red Tortoise LLC
Atlanta,
Georgia
| – | -$1.1K | -230 | Closed |
|
|
AF
129
Allworth Financial
Folsom,
California
| – | -$187 | -39 | Closed |
|
PMVP Hedge Fund Activity: Q2 2023 in Review
106 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q2 2023, worth a combined $324M — up 32% from $246M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of PMVP and 18 opened new positions — a net loss of 5 holders — while 29 trimmed existing stakes and 40 added.
The largest buyer was Bank of Montreal, opening a new position worth an estimated $3.66M. The largest seller was Bank of America, cutting an estimated $3.86M.
- 106 institutional investors held PMV Pharmaceuticals (PMVP) as of Q2 2023, down from 111 in Q1 2023.
- Funds reported $324M of PMV Pharmaceuticals stock for Q2 2023, up 32% quarter-over-quarter.
- 18 funds opened new PMV Pharmaceuticals positions in Q2 2023 and 23 closed out, a net change of -5 holders.
- The largest PMV Pharmaceuticals buyer in Q2 2023 was Bank of Montreal, an estimated $3.66M added.
- The largest PMV Pharmaceuticals seller in Q2 2023 was Bank of America, an estimated $3.86M sold.
Based on aggregated 13F filings for Q2 2023.